Related references
Note: Only part of the references are listed.Adherence to the Mediterranean diet is inversely associated with metabolic syndrome occurrence: a meta-analysis of observational studies
Justyna Godos et al.
INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION (2017)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Elena Buzzetti et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence
Alessandro Federico et al.
TRANSLATIONAL RESEARCH (2016)
Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe
Arnolfo Petruzziello et al.
INFECTIOUS AGENTS AND CANCER (2016)
Alcoholic Liver Disease and Hepatitis C Chronic Infection
Alessandro Federico et al.
REVIEWS ON RECENT CLINICAL TRIALS (2016)
Mitochondrial proteolysis: Its emerging roles in stress responses
Shiori Sekine et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2015)
Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition
H. B. Li et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2015)
Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States From 2004 to 2009
Zobair M. Younossi et al.
HEPATOLOGY (2015)
Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product
Eirini Christodoulou et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats
Simona Clichici et al.
JOURNAL OF MEDICINAL FOOD (2015)
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients
Dominique L. Braun et al.
PLOS ONE (2015)
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics
Harel Dahari et al.
LIVER INTERNATIONAL (2015)
Oxidative stress modulation in hepatitis C virus infected cells
Sonia A. Lozano-Sepulveda et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
New silibinin glyco-conjugates: Synthesis and evaluation of antioxidant properties
Armando Zarrelli et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis
Gaetano Serviddio et al.
FREE RADICAL BIOLOGY AND MEDICINE (2014)
Pathological Features of Fatty Liver Disease
Matthew M. Yeh et al.
GASTROENTEROLOGY (2014)
Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
Christophe Hezode et al.
GASTROENTEROLOGY (2014)
Is Genotype 3 of the Hepatitis C Virus the New Villain?
Nicolas Goossens et al.
HEPATOLOGY (2014)
Identification of Isosilybin A from Milk Thistle Seeds as an Agonist of Peroxisome Proliferator-Activated Receptor Gamma
Eva-Maria Pferschy-Wenzig et al.
JOURNAL OF NATURAL PRODUCTS (2014)
Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study
Paola Stiuso et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2014)
US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity?
Vinay Prasad et al.
PLOS ONE (2014)
Effects and Tolerance of Silymarin (Milk Thistle) in Chronic Hepatitis C Virus Infection Patients: A Meta-Analysis of Randomized Controlled Trials
Zongguo Yang et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Non Alcoholic Fatty Liver: Epidemiology and Natural History
Mario Masarone et al.
REVIEWS ON RECENT CLINICAL TRIALS (2014)
Down-regulation of LPCAT expression increases platelet-activating factor level in cirrhotic rat liver: Potential antiinflammatory effect of silybin
Eleonora Stanca et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver
Jiayin Yao et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2013)
Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking
Julie Blaising et al.
CELLULAR MICROBIOLOGY (2013)
Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B
F. Wei et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2013)
A 360-degree overview of paediatric NAFLD: Recent insights
Valerio Nobili et al.
JOURNAL OF HEPATOLOGY (2013)
Milk Thistle and Its Derivative Compounds: A Review of Opportunities for Treatment of Liver Disease
E. S. Hackett et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2013)
Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma
Ramakrishnan Gopalakrishnan et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not
Zobair M. Younossi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes
Ignazio Grattagliano et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Metabolic effects of silibinin in the rat liver
Carina Parisoto Colturato et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2012)
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial
Carmela Loguercio et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease
Srinevas K. Reddy et al.
HEPATOLOGY (2012)
Characterization of Telaprevir Treatment Outcomes and Resistance in Patients With Prior Treatment Failure: Results From the REALIZE Trial
Sandra De Meyer et al.
HEPATOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways
Jir-You Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Understanding silibinin's modes of action against HCV using viral kinetic modeling
Jeremie Guedj et al.
JOURNAL OF HEPATOLOGY (2012)
Biochemical and immunological basis of silymarin effect, a milk thistle (Silybum marianum) against ethanol-induced oxidative damage
Subir Kumar Das et al.
TOXICOLOGY MECHANISMS AND METHODS (2012)
Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy
Karoline Rutter et al.
ANTIVIRAL THERAPY (2011)
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Kohichiroh Yasui et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Therapeutic efficacy of silymarin and naringenin in reducing arsenic-induced hepatic damage in young rats
Anshu Jain et al.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY (2011)
Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis
Yara Haddad et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2011)
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
Michael R. Charlton et al.
GASTROENTEROLOGY (2011)
Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation
Jessica Wagoner et al.
PLOS ONE (2011)
Investigating the Potential for Toxicity from Long-Term Use of the Herbal Products, Goldenseal and Milk Thistle
June K. Dunnick et al.
TOXICOLOGIC PATHOLOGY (2011)
Silybin and the liver: From basic research to clinical practice
Carmela Loguercio et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Suppression of Casein Kinase 1α in Melanoma Cells Induces a Switch in β-Catenin Signaling to Promote Metastasis
Tobias Sinnberg et al.
CANCER RESEARCH (2010)
Platelet-Activating Factor Involvement in Thioacetamide-Induced Experimental Liver Fibrosis and Cirrhosis
Haralabos C. Karantonis et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
Abdelhakim Ahmed-Belkacem et al.
GASTROENTEROLOGY (2010)
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Brad Q. Starley et al.
HEPATOLOGY (2010)
Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle
Jessica Wagoner et al.
HEPATOLOGY (2010)
Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C
Roy L. Hawke et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy
U. P. Neuman et al.
JOURNAL OF HEPATOLOGY (2010)
Nonobese individuals in the developing world are at risk of nonalcoholic fatty liver and liver disease
Natalie J. Wood
Nature Reviews Gastroenterology & Hepatology (2010)
Identification of hepatoprotective flavonolignans from silymarin
Stephen J. Polyak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder
Mehdi Sayyah et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats
Omar Mohamed E. Abdel Salam et al.
INFLAMMOPHARMACOLOGY (2010)
PCNA on the crossroad of cancer
Ivaylo Stolimenov et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Noreen Hossain et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells
Marco Trappoliere et al.
JOURNAL OF HEPATOLOGY (2009)
Causes and Metabolic Consequences of Fatty Liver
Norbert Stefan et al.
ENDOCRINE REVIEWS (2008)
Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation
Majid Momeny et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy
Peter Ferenci et al.
GASTROENTEROLOGY (2008)
Inflammation and endoplasmic reticulum stress in obesity and diabetes
G. S. Hotamisligil
INTERNATIONAL JOURNAL OF OBESITY (2008)
Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes
Dominique Detaille et al.
LIFE SCIENCES (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis
Nora Anderson et al.
PHARMACOLOGICAL REVIEWS (2008)
Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis
Yin-Ying Lu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
An updated systematic review with meta-analysis for the clinical evidence of silymarin
Reinhard Saller et al.
FORSCHENDE KOMPLEMENTARMEDIZIN (2008)
Wnt signalling and its impact on development and cancer
Alexandra Klaus et al.
NATURE REVIEWS CANCER (2008)
Effects and mechanisms of silibinin on human hepatoma cell lines
John J. Lah et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs
H. N. Varzi et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2007)
Protective effect of silymarin on erythrocyte haemolysate against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress
P. V. Kiruthiga et al.
CHEMOSPHERE (2007)
The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: A pilot study
Carmela Loguercio et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
Thomas W. Flaig et al.
INVESTIGATIONAL NEW DRUGS (2007)
Protective effect of silymarin on oxidative stress in rat brain
C. Nencini et al.
PHYTOMEDICINE (2007)
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
Michael T. Lin et al.
NATURE (2006)
Angiogenesis and cell proliferation in human craniopharyngioma xenografts in nude mice
Jianguo Xu et al.
JOURNAL OF NEUROSURGERY (2006)
Chemotherapeutic efficacy of paclitaxel in combination with Withania somnifera on benzo(a)pyrene-induced experimental lung cancer
Palaniyandi Senthilnathan et al.
CANCER SCIENCE (2006)
Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice
Syed M. Meeran et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Platelet-activating factor in liver injury: A relational scope
Nikolaos P. Karidis et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Silymarin protects against acute ethanol-induced hepatotoxicity in mice
ZY Song et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2006)
A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with nonalcoholic fatty liver disease: preliminary observations
A. Federico et al.
GUT (2006)
Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication
FA Crocenzi et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation
M Plísková et al.
TOXICOLOGY (2005)
Silymarin treatment of viral hepatitis:: a systematic review
KÉ Mayer et al.
JOURNAL OF VIRAL HEPATITIS (2005)
Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment:: Effect of silymarin, silibimn, colchicine and trimethylcolchicinic acid
P Muriel et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
DS Cai et al.
NATURE MEDICINE (2005)
Ursodeoxycholic acid protects against secondary billary cirrhosis in rats by preventing mitochondrial oxidative stress
G Serviddio et al.
HEPATOLOGY (2004)
Prostate cancer prevention by silibinin
RP Singh et al.
CURRENT CANCER DRUG TARGETS (2004)
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages
A Tyagi et al.
CARCINOGENESIS (2004)
Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact
Michael Charlton
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Analysis of glycoconjugates in patients with oral squamous cell carcinoma
S Manoharan et al.
CLINICA CHIMICA ACTA (2004)
Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis
Y Yang et al.
GUT (2004)
Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients
MG Tutton et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons
CS Lieber et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2003)
Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells
SZ Zhang et al.
PHARMACEUTICAL RESEARCH (2003)
Protection against post-ischemic mitochondrial injury in rat liver by silymarin or TUDC
AP Rolo et al.
HEPATOLOGY RESEARCH (2003)
Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum)
NC Kim et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2003)
Expression of β-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression
M Joo et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2003)
Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport
SH Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Effect of flavonoids on MRP1-mediated transport in Panc-1 cells
H Nguyen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Validating survivin as a cancer therapeutic target
DC Altieri
NATURE REVIEWS CANCER (2003)
Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation
MJ Wang et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
A central role for JNK in obesity and insulin resistance
J Hirosumi et al.
NATURE (2002)
Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism
CM Liu et al.
CELL (2002)
Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1(I) and TIMP-1
JD Jia et al.
JOURNAL OF HEPATOLOGY (2001)
Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells
Y Sharma et al.
MOLECULAR CARCINOGENESIS (2001)
The use of silymarin in the treatment of liver diseases
R Saller et al.
DRUGS (2001)
Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents
R Agarwal
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
